2021. Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer. Biomolecules and Biomedicine. 21, 2 (Apr. 2021), 198–207. DOI:https://doi.org/10.17305/bjbms.2020.4746.